Scailyte translates first biomarker into a diagnostics application


Scailyte is an ETH Zürich Spin-off applying artificial intelligence to discover novel and ultra-sensitive biomarkers from single-cell data. The start-up is currently translating its first single-cell biomarker for the detection of skin T-cell lymphoma into an in vitro diagnostics application. In order to strengthen Scailyte’s discovery potential and provide strategic guidance, the company has appointed a scientific advisory board.


Over the past 3 years, Scailyte has established ScaiVision, a proprietary data analytics platform for clinical research, which enables the company to achieve groundbreaking discoveries in multiple disease areas. The team has validated its approach by discovering a first single-cell biomarker for the detection of skin T-cell lymphoma, which they are currently translating into an in vitro diagnostics application that will radically improve the diagnosis and survival chances for thousands of patients suffering from this disease.

Scailyte is now scaling up its efforts by applying the biomarker discovery approach for multiple indications in oncology and women’s health. Two biomarkers are already in the discovery phase among them one biomarker for the prediction of therapy response in an oncology indication. Seven new indications will be added in 2021. 

This week the team announced, that they have appointed a scientific advisory board consisting of world leading clinicians and scientists to strengthen Scailyte’s discovery potential and provide strategic guidance. The scientific advisory board is being led by Scailyte's co-founder, Professor Dr. Manfred Claasen. “Scailyte’s mission is to provide better healthcare and transform diagnostics, with particular focus on diseases with high unmet diagnostic need. With the rise of novel single-cell technologies, we are now in the unique position to leverage the potential of high dimensional single-cell data and Scailyte is at the forefront of turning this potential into clinical applications. ” says Prof. Claassen. Prof. Dr. Manfred Claassen has been recently appointed as full professor in Clinical Bioinformatics at the University Hospital of Tübingen with focus on machine learning for single-cell biology and precision medicine.

The other members of the scientific advisory board include:

Prof. Dr. Emmanuella Guenova is a dermatologist, specialist in cutaneous lymphoma and laboratory diagnostics of skin diseases, and appointed professor at the Faculty of Biology and Medicine of the University of Lausanne. Prof. Guenova is supporting Scailyte as a clinical advisor and principal investigator in our clinical development program for cutaneous T-cell lymphoma.

Prof. Dr. Michael Mueller is a renowned gynaecologist and gynecological oncologist, and managing director of the Women's Health Clinic at the University Hospital of Bern (Inselspital). Prof. Mueller is supporting Scailyte as a clinical advisor and expert in endometriosis and women’s health.

Prof. Dr. Tomas Kalina is a physician and a cytometry expert currently leading a research group focused on disorders of adaptive immunity at the Charles University in Prague. Professor Kalina is supporting Scailyte as a clinical diagnostic advisor with his expertise in cytometry standardization.

Prof. Dr. Petter Brodin is a pioneer in single-cell analysis and, advising Scailyte in immunology and the application of single-cell technologies for clinical research.

Dr. Michael Stadler is a staff scientist and leads the computational biology group at the Friedrich Miescher Institute for Biomedical Research (FMI) Basel. He is a scientific advisor supporting Scailyte’s with the development of its data analytics platform.

(Press release / SK)